ReviewInflammopharmacology2026
RGRN-305, a novel Hsp90 inhibitor: a promising therapeutic option for inflammatory dermatologic diseases.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heat shock protein 90 (Hsp90) is a molecular chaperone that plays a critical role in cellular homeostasis and influences various cellular processes. Recent research has revealed its involvement in inflammatory skin diseases, suggesting that Hsp90 inhibitors, such as RGRN-305, may offer therapeutic potential for dermatologic inflammation. This review aims to evaluate the therapeutic role of RGRN-305, a novel Hsp90 inhibitor, in the treatment of inflammatory dermatologic diseases. A comprehensive search was conducted in PubMed/Medline, Scopus, and Web of Science databases up to February 13th, 2025, using keywords related to Hsp90 and RGRN-305, and seven studies were included in the study. Preclinical evidence has demonstrated that RGRN-305 effectively reduces inflammation and modulates immune responses in psoriasis and other skin diseases. Clinical trials revealed significant improvements in disease severity and quality of life for patients with psoriasis and hidradenitis suppurativa treated with RGRN-305. The drug exhibited favorable pharmacokinetic properties, including oral bioavailability, without central nervous system-related toxicity. Safety profiles indicated mild to moderate adverse effects, with no severe events reported in most studies. RGRN-305 shows promising potential as an anti-inflammatory agent in the treatment of autoimmune dermatologic diseases. Larger, randomized clinical trials are required to establish its long-term efficacy and safety.
Indexed as
Identifiers
42176147What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.